Your browser doesn't support javascript.
loading
Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.
Wang, Yemin; Chen, Shary Yuting; Colborne, Shane; Lambert, Galen; Shin, Chae Young; Santos, Nancy Dos; Orlando, Krystal A; Lang, Jessica D; Hendricks, William P D; Bally, Marcel B; Karnezis, Anthony N; Hass, Ralf; Underhill, T Michael; Morin, Gregg B; Trent, Jeffrey M; Weissman, Bernard E; Huntsman, David G.
Affiliation
  • Wang Y; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. yewang@bccrc.ca dhuntsma@bccancer.bc.ca.
  • Chen SY; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
  • Colborne S; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Lambert G; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
  • Shin CY; Michael Smith Genome Science Centre, British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Santos ND; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
  • Orlando KA; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
  • Lang JD; Department of Experimental Therapeutics, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
  • Hendricks WPD; Department of Pathology and Laboratory Medicine and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
  • Bally MB; Division of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, Arizona.
  • Karnezis AN; Division of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, Arizona.
  • Hass R; Department of Experimental Therapeutics, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
  • Underhill TM; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Morin GB; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
  • Trent JM; Department of Obstetrics and Gynecology, Hannover Medical School, D-30625 Hannover, Germany.
  • Weissman BE; Department of Cellular and Physiological Sciences and Biomedical Research Centre, University of British Columbia, Vancouver, BC, Canada.
  • Huntsman DG; Michael Smith Genome Science Centre, British Columbia Cancer Agency, Vancouver, BC, Canada.
Mol Cancer Ther ; 17(12): 2767-2779, 2018 12.
Article in En | MEDLINE | ID: mdl-30232145
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Carcinoma, Small Cell / Histone Deacetylase Inhibitors / Enhancer of Zeste Homolog 2 Protein / Hypercalcemia / Antineoplastic Agents Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Mol Cancer Ther Journal subject: ANTINEOPLASICOS Year: 2018 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Carcinoma, Small Cell / Histone Deacetylase Inhibitors / Enhancer of Zeste Homolog 2 Protein / Hypercalcemia / Antineoplastic Agents Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Mol Cancer Ther Journal subject: ANTINEOPLASICOS Year: 2018 Document type: Article Country of publication: United States